With
the post-antibiotic era rapidly approaching, many have turned
their attention to developing new treatments, often by structural
modification of existing antibiotics. Polymyxins, a family of lipopeptide
antibiotics that are used as a last line of defense in the clinic,
have recently developed resistance and exhibit significant nephrotoxicity
issues. Using thiol–ene chemistry, the facile preparation of
six unique S-lipidated building blocks was demonstrated and used to
generate lipopeptide mimetics upon incorporation into solid-phase
peptide synthesis (SPPS). We then designed and synthesized 38 polymyxin
analogues, incorporating these unique building blocks at the N-terminus,
or to replace hydrophobic residues at positions 6 and 7 of the native
lipopeptides. Several polymyxin analogues bearing one or more S-linked lipids were found to be equipotent to polymyxin,
showed minimal kidney nephrotoxicity, and demonstrated activity against
several World Health Organisation (WHO) priority pathogens. The S-lipidation
strategy has demonstrated potential as a novel approach to prepare
innovative new lipopeptide antibiotics.